Piper Sandler analyst Allison Bratzel downgraded Inozyme (INZY) to Neutral from Overweight with a $4 price target after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme downgraded to Hold from Buy at Jefferies
- Leerink bullish on BioMarin following Inozyme deal, expects additional BD
- Inozyme downgraded to Market Perform from Outperform at Raymond James
- Inozyme downgraded to Hold from Buy at Needham
- Inozyme downgraded to Equal Weight from Overweight at Wells Fargo